You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
|
|---|---|
| Published in |
JAMA Oncology, August 2020
|
| DOI | 10.1001/jamaoncol.2020.2091 |
| Pubmed ID | |
| Authors |
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schütte, Silke Cameron, Peter Hohenberger, Philipp J. Jost, Salah-Eddin Al-Batran, Lars H. Lindner, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Raija Kallio, Panu Jaakkola, Jouni Junnila, Thor Alvegård, Peter Reichardt |
X Demographics
The data shown below were collected from the profiles of 59 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 17% |
| Japan | 4 | 7% |
| United Arab Emirates | 2 | 3% |
| Spain | 2 | 3% |
| India | 2 | 3% |
| Brazil | 1 | 2% |
| Finland | 1 | 2% |
| Colombia | 1 | 2% |
| France | 1 | 2% |
| Other | 5 | 8% |
| Unknown | 30 | 51% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 40 | 68% |
| Practitioners (doctors, other healthcare professionals) | 12 | 20% |
| Scientists | 4 | 7% |
| Science communicators (journalists, bloggers, editors) | 3 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 18% |
| Student > Bachelor | 6 | 8% |
| Student > Doctoral Student | 5 | 7% |
| Other | 4 | 6% |
| Professor | 3 | 4% |
| Other | 14 | 19% |
| Unknown | 27 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 42% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Veterinary Science and Veterinary Medicine | 1 | 1% |
| Other | 4 | 6% |
| Unknown | 27 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2020.
All research outputs
#1,258,406
of 25,837,817 outputs
Outputs from JAMA Oncology
#1,708
of 3,345 outputs
Outputs of similar age
#34,992
of 427,670 outputs
Outputs of similar age from JAMA Oncology
#59
of 101 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,345 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 84.3. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 427,670 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.